Afasci, Inc.
Burlingame, CA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 2633 Martinez Dr, Burlingame, CA 94010, USA
- Website
- afasci.com
- Founded
- 2003
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| FY13: "phenotypic screening of smoking cessation drugs," N43DA-13-7786: purpose: to fund base award of sbir phase I… | National Institute on Drug Abuse (NIH) | $338,884 |
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| Board Of Regents Of The University Of Nebraska | R01NS127439 | $165,990 | |
| Board Of Regents Of The University Of Nebraska | R01NS127439 | $149,904 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Epigen Biosciences Inc. | San Diego, CA | 325199 All Other Basic Organic Chemical Manufacturing |
| Camino Pharma LLC | San Diego, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Amygdala Neurosciences, Inc. | Palo Alto, CA | — |
| Regulonix LLC | Gainesville, FL | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Raft Pharmaceuticals LLC | San Diego, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Afasci, Inc., doing business as Afasci Research Laboratories, is a San Francisco Bay Area biotech company that conducts research and development in biotechnology and therapeutics. Afasci has not received any prime federal contract awards. The company received one federal contract subaward from SRI International to conduct a rodent pharmacokinetic study.
Through federal grants, Afasci has focused on developing medications to treat substance use disorders and neuropathic pain. This includes a $483,851 cooperative agreement from the National Institute on Alcohol Abuse and Alcoholism to develop a novel medication for alcohol use disorder. Afasci also received a $4,499,793 project grant from the National Institute of Neurological Disorders and Stroke to conduct clinical Phase I trials on AFA-281, a non-opioid medication for neuropathic pain. Additionally, the company was awarded a $319,547 project grant from the National Institute on Drug Abuse to develop a treatment for cocaine use disorder using its investigational new drug AFA-281. Afasci has also received one federal grant subaward from the University of Nebraska related to discovery and evaluation of pain medications.
Quick answers
Is Afasci, Inc. registered in SAM.gov?
Yes. Afasci, Inc.'s SAM.gov registration is active through September 17, 2027.
What is Afasci, Inc.'s CAGE code?
Afasci, Inc.'s CAGE code is 43M05, and its Unique Entity ID (UEI) is UGMEBNM4WSL6.
What is Afasci, Inc.'s most recent federal award?
Afasci, Inc.'s most recent federal grant award is Development of a novel medication for alcohol use disorder with an active IND dual inhibitor of T-type calcium… (U43AA031391), from National Institute on Alcohol Abuse and Alcoholism (NIH), on September 25, 2023.
On GovTribe
See Afasci, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors